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Hodgkin lymphoma: epidemiology, 
histopathology, staging, and treatment
Epidemiology
The  age-standardized  incidence  rate  of  Hodgkin 
lymphoma  (HL)  is  1  per  100,000,  with  a  worldwide 
incidence  of  67,887  cases  in  2008  [1].  HL  comprises 
approximately 11% of all lymphomas in western countries 
and has a bimodal age distribution, with a first peak in 
young adults and a second peak around 59 years of age 
[1,2].  HL  is  currently  classified  as  two  distinct  disease 
entities: nodular lymphocyte-predominant HL (NLPHL) 
and  classical  Hodgkin  lymphoma  (cHL)  [2,3].  In  fact, 
these  histologic  subtypes  have  different  clinical 
presentations, age distributions, and prognoses. From a 
biological  and  clinical  point  of  view,  NLPHL  is  now 
viewed as a distinct disease entity that is more similar to 
indolent B-cell non-HL than to cHL [3]. The prognosis 
for patients with NLPHL is usually good, sometimes even 
without  treatment  [2,4].  A  recent  study  showed  that 
NLPHL  is  characterized  by  a  distinct  gene-expression 
signature [5].
Histopathology
The  characteristic  Hodgkin  and  Reed-Sternberg  (HRS) 
cells in cHL, and the lymphocytic and histiocytic (L and 
H)  cells  in  NLPHL,  account  for  only  1%  to  5%  of  the 
entire  tumor  mass  and  grow  in  a  unique  tumor 
microenvironment  composed  of  many  different  cell 
types,  including  T  cells,  B  cells,  macrophages, 
neutrophils,  eosinophils,  plasma  cells,  mast  cells,  and 
fibroblasts [3].
cHL  is  further  divided  into  four  histologic  subtypes: 
nodular-sclerosis classical Hodgkin lymphoma (NSCHL), 
lymphocyte-rich classical Hodgkin lymphoma (LRCHL), 
mixed-cellularity  classical  Hodgkin  lymphoma 
(MCCHL), and lymphocyte-depletion classical Hodgkin 
lymphoma (LDCHL) [2]. Although this classification is 
mainly  based  on  histopathology,  taking  into  account 
differences in the composition of the reactive infiltrate 
and stroma, recent studies have demonstrated that these 
disease entities are biologically different, with different 
genomic alterations, gene-expression patterns, cytokine 
milieu,  and  clinical  behavior  [6,7].  The  epidemiology, 
clinical presentation, and prognosis of these subtypes are 
also different [8], but these differences have not yet been 
translated into changes in the treatment approach, since 
the  adriamycin  (doxorubicin),  bleomycin,  vinblastine, 
dacarbazine (ABVD) chemotherapy regimen remains the 
mainstay for the treatment of all cHL subtypes.
Abstract
Classical Hodgkin lymphoma is considered a highly 
curable disease; however, 20% of patients cannot be 
cured with standard first-line chemotherapy and have 
a dismal outcome. Current clinical parameters do not 
allow accurate risk stratification, and personalized 
therapies are lacking. In fact, Hodgkin lymphoma (HL) 
is often over- or undertreated because of this lack of 
accurate risk stratification. In recent years, the early 
detection of chemoresistance by fluorodeoxyglucose 
positron emission tomography has become the most 
important prognostic tool in the management of HL. 
However, to date, no prognostic scores or molecular 
markers are available for the early identification of 
patients at very high risk of failure of induction therapy. 
In the last decade, many important advances have 
been made in understanding the biology of HL. In 
particular, the development of new molecular profiling 
technologies, such as SNP arrays, comparative genomic 
hybridization, and gene-expression profiling, have 
allowed the identification of new prognostic factors 
that may be useful for risk stratification and predicting 
response to chemotherapy. In this review, we focus on 
the prognostic tools and biomarkers that are available 
for newly diagnosed HL, and we highlight recent 
advances in the genomic characterization of classical 
HL and potential targets for therapy.
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© 2011 BioMed Central LtdNSCHL  affects  young  adults,  is  more  common  in 
females, and frequently involves the mediastinum, which 
comprises the tissues and organs of the chest, excluding 
the lungs. It is less frequently associated with Epstein-
Barr  virus  (EBV)  infection  and  probably  requires  an 
intact  immune  system  to  develop,  as  the  incidence  in 
HIV-positive patients declines as the number of CD4+ 
lymphocytes declines [2,9]. Several studies using gene-
expression  profiling  and  expression  of  surface  markers 
have suggested a link between mediastinal NSCHL and 
primary mediastinal B-cell lymphoma [10]. In contrast, 
MCCHL and LDCHL have epidemiological and clinical 
features  that  are  distinct  from  NSCHL:  they  are  more 
frequent in males, have a bimodal age distribution, are 
frequently associated with EBV and HIV infection, and 
normally  spare  the  mediastinum.  The  prognosis  for 
MCCHL  and  LDCHL  is  worse  than  for  NSCHL  [2]. 
LRCHL  is  characterized  by  older  age  at  presentation, 
infrequent  mediastinal  involvement,  and  excellent 
prognosis  [2,8,11].  The  clinical  characteristics  of  the 
different subtypes of cHL are listed in Table 1.
Current staging and treatment
cHL is generally considered a highly curable disease, with 
approximately 80% of patients cured with standard first-
line chemotherapy. Approximately 15% to 20% of patients 
with limited-stage (that is, stage I to II) disease and 35% 
to 40% of patients with advanced-stage (stage III to IV) 
disease have disease relapse or disease that is refractory 
to  first-line  chemotherapy  [12,13].  Current  first-line 
therapy  consists  of  four  to  six  cycles  of  ABVD 
chemotherapy  [14]  followed  by  radiotherapy  when 
indicated  [15-17].  About  half  of  all  patients  who  have 
disease  relapse  after  first-line  chemotherapy  have  their 
disease successfully treated with high-dose chemotherapy 
followed by autologous stem cell transplantation [18,19]. 
The treatment decision algorithm for cHL is based on 
clinical parameters: the Ann Arbor staging system is the 
main staging system used and allows distinction between 
early-stage  and  advanced-stage  disease  [20];  the 
International Prognostic Score (IPS) is the standard for 
risk stratification of patients with advanced disease (0 to 
7 scale), but is not applicable to patients with early-stage 
HL [21]. This very simplified risk stratification determines 
the  lack  of  differentiated  and  personalized  treatment 
options in clinical practice. For this reason, HL is often 
over- or undertreated [22,23].
Cytotoxic chemotherapy may lead to short- and long-
term toxicities that can affect the final outcome; a recent 
study of reduced treatment intensity in early-stage HL 
found that even though more than 90% of patients were 
disease-free 5 years after the initial diagnosis following 
chemoradiotherapy, the first cause of death during the 
follow-up  period  was  secondary  neoplasia,  and  more 
than 50% of all deaths (4.8% of all patients) were possibly 
related to the delivered treatment [24]. Because HL is a 
highly  curable  cancer,  future  research  is  focusing  on 
identifying patients with a low probability of cure and 
who  may  benefit  from  more  novel  and/or  intensive 
therapies,  and  those  with  a  high  probability  of  having 
their disease cured and who may be suitable for less toxic 
therapies.  Thus,  better  risk  stratification  is  needed  to 
develop strategies aimed at improving the cure rate while 
reducing treatment-related toxicity.
In  recent  years,  fluorodeoxyglucose  (FDG)  positron 
emission tomography (PET) (FDG-PET) has significantly 
changed the management of HL: it is now the basis for 
the initial staging and risk-adapted therapy approach. In 
fact, early-interim FDG-PET (a PET scan performed after 
two cycles of ABVD chemotherapy) has emerged as the 
most important prognostic tool in HL [25-27], and many 
ongoing clinical trials are testing the role of interim PET-
oriented therapy in HL [28]. This early-interim imaging is 
most  relevant  for  early-stage  disease  in  which  overall 
survival  (OS)  is  compromised  by  treatment-related 
mortality (mainly long-term toxicities of the treatment 
regimen;  these  include  secondary  tumors  and 
cardiovascular events) [24].
In the last decade, many important advances have been 
made in understanding the biology of HL. In particular, 
new molecular profiling technologies, such as genome-
copy  number  analysis  with  SNP  arrays  or  array 
Table 1. Current clinical presentation and management of Hodgkin lymphoma
Histology  Incidence (%)  Age at diagnosis  Clinical characteristics  Treatment  Outcome, PFS (%)
cHL  95  Bimodal     
NSCHL  70  Young adults (10 to 30 years)  Frequent mediastinal involvement  ABVD±RT  80
MCCHL  10 to 25  Bimodal distribution, 3rd to 7th decade  Infrequent mediastinal involvement  ABVD±RT  <80
LDCHL  1  Bimodal distribution, 3rd to 7th decade  Infrequent mediastinal involvement  ABVD±RT  <80
LRCHL  1  Bimodal distribution, 3rd to 7th decade  Infrequent mediastinal involvement  ABVD±RT  >90
NLPHL  5  4th decade  Infrequent mediastinal involvement  ABVD±RT,  Good prognosis,  
        rituximab  multiple relapses
ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; cHL, classical Hodgkin lymphoma; LDCHL, lymphocyte-depletion classical Hodgkin lymphoma; LRCHL, 
lymphocyte-rich classical Hodgkin lymphoma; MCCHL, mixed-cellularity classical Hodgkin lymphoma; NLPHL, nodular lymphocyte-predominant Hodgkin lymphoma; 
NSCHL, nodular-sclerosis classical Hodgkin lymphoma; PFS, progression-free survival; RT, radiotherapy.
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expression  profiling,  have  allowed  the  identification  of 
new  prognostic  factors  that  may  be  useful  for  risk 
stratification and predicting response to chemotherapy. 
This  review  summarizes  the  prognostic  tools  and 
biomarkers  that  are  available  for  characterizing  newly 
diagnosed HL, and highlights recent advances in genomic 
studies  of  cHL  and  their  implications  for  predicting 
treatment outcome and for identifying potential targets 
for therapy.
Identifying genes associated with an increased risk 
of HL
Recent advances in the genomic characterization of HL 
have led to a better understanding of HL pathobiology. 
Several  studies  have  assessed  the  association  between 
SNPs in cytokine genes and risks of developing different 
cancers, including HL. In a recent study, Monroy et al. 
(2011) compared 200 HL cases and 220 controls to assess 
the  relationship  between  genetic  polymorphisms  in 
cytokine genes and susceptibility for developing HL [29]. 
SNPs  for  38  preselected  genes  involved  in  cytokine 
signaling  were  considered.  Interestingly,  the  authors 
found  a  correlation  between  a  combination  of  allelic 
variants  of  COX2,  IL18,  ILR4,  and  IL10  and  risk  of 
developing HL. These results highlight the importance of 
the  tumor  microenvironment  and  the  role  of  aberrant 
cytokine signaling in the pathogenesis of HL. In addition, 
using the same study group, Monroy et al. (2011) showed 
that genetic variants in DNA repair genes are significantly 
correlated with the risk of HL [30]. A similar method was 
used  to  identify  susceptibility  loci  for  cHL  in  a  recent 
study considering 589 cHL cases and 5,199 controls [31]. 
Three new susceptibility loci were identified that map to 
chromosome  2p16.1  (corresponding  to  the  REL  gene, 
encoding c-REL, a member of the NF-kB family), 8q24.21 
(encompassing PVT1, a gene involved in MYC-mediated 
lymphomagenesis),  and  10p14  (which  contains  the 
GATA3  gene,  a  master  regulator  of  T2  differentiation) 
[31].
In  another  study,  Lorenzo  and  colleagues  used  a 
genomic  approach  to  detect  differential  expression  of 
genes  potentially  involved  in  the  development  of 
secondary neoplasms in HL patients [32]. The incidence 
of secondary tumors in HL patients has historically been 
linked mainly to age and type of treatment received, with 
the highest risk related to the use of radiation therapy 
and alkylating agents. In that study, the levels of DNA 
damage, DNA damage repair capabilities, and differential 
expression of a set of genes involved in these pathways 
were analyzed in three groups of patients: those with HL 
who  developed  a  second  neoplasm,  those  with  HL 
without  a  second  neoplasm,  and  healthy  controls.  The 
level of DNA damage was higher in the patients with HL 
who had secondary tumors than in the patients with HL 
who did not develop secondary tumors, and was higher 
in the patients with HL without secondary tumors than 
in  the  healthy  controls.  In  addition,  a  set  of  genes 
involved in DNA repair, drug metabolism, the cell cycle, 
and cell proliferation was differentially expressed across 
the three groups. These results are of particular interest 
because constitutive defects in DNA repair mechanisms 
and increased sensitivity to carcinogens may potentially 
be involved in the development and pathogenesis of HL, 
as well as secondary neoplasms.
Predicting disease outcome in HL
Recent advances in our understanding of HL biology and 
interactions  between  HRS  cells  and  the  tumor 
microenvironment  have  led  to  the  development  of 
potential new prognostic factors, biomarkers of disease 
activity, and targets for therapy.
Expression of Bcl-2 and p53
Several retrospective studies have evaluated prognostic 
factors that are linked to HRS cell biology, such as p53 
and Bcl-2 expression, by immunohistochemical analysis 
[33]. Bcl-2 and p53 have opposite roles in tumorigenesis. 
Bcl-2 overexpression leads to cell survival by inhibiting 
apoptosis [34,35], whereas p53 is essential for regulating 
cell death by inducing apoptosis following cell damage in 
response to cytotoxic agents [36-38]. Although defective 
p53 function has been related to chemoresistance in a 
variety of tumors [36,39,40], no such data exist for HL 
[41], perhaps because of the great variability among the 
results of various studies regarding p53 production (p53 
production  varies  from  10%  to  90%  in  cHL  [42-44]) 
[44-46].
The antiapoptotic factor Bcl-2 may be involved in the 
pathogenesis of cHL, as it has been shown that HRS cells 
are  derived  from  germinal-center  B  cells  that  lack 
immunoglobulin expression [3]. Normally, these aberrant 
cells undergo apoptosis, but dysregulation of the Bcl-2 
pathway may provide a way for the cells to escape the 
apoptotic program [3]. The prognostic value of Bcl-2 in 
cHL  has  been  extensively  examined  in  several  studies 
[33,44,46-50].  Two  independent  studies  specifically 
examining the prognostic role of Bcl-2 expression have 
shown that Bcl-2 is an independent factor that predicts 
poor prognosis in cHL when considered together with 
clinical variables [33,47].
Other  prognostic  biomarkers  evaluated  by 
immunohistochemical analysis that have been shown to 
correlate with adverse outcomes are topoisomerase IIα (a 
ubiquitous  enzyme  that  plays  an  essential  role  in  the 
control of replicative DNA synthesis), human leukocyte 
antigen class II, and myelin and lymphocyte protein (a 
membrane  protein  involved  in  lipid-raft  organization 
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immunohistochemical markers related to HRS cells are 
shown in Table 2.
Immunohistochemical studies on infiltrating T cells
HRS  cells  are  involved  in  regulating  the  cellular 
composition  of  the  microenvironment  by  secreting 
cytokines and chemokines that selectively attract certain 
cells [56]. For example, CD4+ T-helper cells are attracted 
by HRS cells through secretion of the chemokines TARC 
(thymus  and  activation-regulated  chemokine)  and 
RANTES  (regulated  upon  activation  normal  T-cell 
expressed, and secreted) [56]. HRS cells can also express 
the programmed death (PD) ligands 1 and 2 that in turn 
interact with regulatory T cells (Tregs) and PD1+ T cells 
[57-59] to promote their immunosuppressive functions. 
In  fact,  regulatory  CD4+  CD25+  T  cells  inhibit  the 
function  of  natural  killer  (NK)  and  CD8+  cytotoxic 
T cells [60]. In this context, FOXP3 (forkhead box P3)+ 
T cells play a major role in converting naive CD4+ CD25- 
T cells into CD4+ CD25+ Tregs [61].
TIA1  (cytotoxic  granule-associated  RNA-binding 
protein) is a marker of CD8+ cytotoxic T cells and its 
production is independent of activation status. Granzyme 
B (GrB) and perforin production are features of NK cells 
and CD8+ activated T cells [62]. Because the absence of 
effective  immune  surveillance  is  related  to  the 
pathogenesis  of  HL  and  the  presence  of  Tregs  is 
correlated  with  poor  outcome  in  solid  tumors  [63], 
several studies have addressed the prognostic impact of 
the  cellular  composition  of  the  microenvironment. 
Surprisingly, three large retrospective studies have shown 
that the presence of intratumoral Tregs, as determined by 
the  identification  of  FOXP3+  cells,  is  associated  with 
better  outcomes  for  patients  with  HL  [50,64,65].  In 
contrast,  increased  numbers  of  cytotoxic  T  cells,  as 
determined by the identification of TIA1 and GrB+ cells 
either individually [66] or in the absence of FOXP3+ cells 
[50],  correlated  with  poor  outcomes.  Recently,  a 
combined prognostic score based on both FOXP3 and 
the macrophage marker CD68 (see next paragraph) was 
examined in a cohort of 122 patients [67]. In preliminary 
findings  when  both  CD68  and  FOXP3  were  used  as 
prognostic markers, the authors identified three different 
prognostic groups, and this prognostic score retained its 
significance for failure-free survival (FFS) and OS in the 
subgroups  of  patients  presenting  with  early-  and 
advanced-stage disease. Importantly, this combined score 
identified a subset of patients with early-stage disease at 
high risk of relapse/progression (5-year FFS, 25%). While 
these  data  apply  to  patients  treated  with  conventional 
combination chemotherapy regimens, it is unknown how 
these  factors  would  influence  treatment  outcomes  in 
patients  treated  with  targeted  therapies.  Table  3 
summarizes the main immunohistochemical prognostic 
markers related to the tumor microenvironment.
Table 2. Prognostic factors related to Hodgkin and Reed-Sternberg cells
Factor Function Number of patients Expression level (%) Significance, univariatea Significance, multivariatea Reference(s)
HLA class II Immune response 292 59 + (↓FFS, OS) + (↓FFS) [51]
Topoisomerase II DNA synthesis 238 
146
64 
49
+ (↓FFS)
+ (↓EFS)
+ (↓FFS)
+ (↓EFS)
[52] 
[49]
MAL T-cell activation   86 
  81
19 
NA
+ (↓FFS, OS)
+ (↓FFS, OS)
+ (↓FFS, OS)
+ (↓FFS)
[54] 
[50]
CD20 B-cell activation (?) 598 
248 
119 
166 
  59
22 
11 
20 
12 
25
– 
+ (↓TTF, OS)
+ (↑TTF)
– 
+ (↑PFS)
– 
+ (↓TTF, OS)
+ (↑TTF)
– 
+ (↑PFS)
[74] 
[73] 
[75] 
[68] 
[48]
p53 Apoptosis; response 
to genotoxic stress
194 
  49 
  78 
259 
140 
107
57 
40 to 75b
67 
29 
92 
10
+ (↓DFS, OS)
– 
– 
+ (↓EFS, DSS)
– 
–
+ (↓DFS, OS)
– 
– 
+ (↓EFS, DSS)
– 
–
[44] 
[42] 
[43] 
[45] 
[46] 
[47]
Bcl-2 Cell survival; anti-
apoptosis
140 
107 
707 
194 
  81 
146 
  59
61 
26 
61 
47 
NA 
40 
33
– 
+ (↓FFS, OS)
+ (↓FFS)
+ (↓DFS)
– 
– 
+ (↓PFS)
– 
+ (↓FFS, OS)
+ (↓FFS)
+ (↓DFS)
+ (↓FFS)
– 
+ (↓PFS)
[46] 
[47] 
[33] 
[44] 
[50] 
[49] 
[48]
aThe presence (+) or absence (–) of a significant correlation (positive ↑ or negative ↓) with the study endpoints.
bTwo different antibodies against p53 were used in this study.
Bcl-2, B-cell lymphoma 2; DSS, disease-specific survival; EFS, event-free survival; FFS, failure-free survival; HLA, human leukocyte antigen; MAL, myelin and lymphocyte 
protein; NA, not applicable; OS, overall survival; PFS, progression-free survival; TTF, time to treatment failure.
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markers
Tumor-associated macrophages
Using  gene  expression  profiling,  Steidl  et  al.  evaluated 
130 fresh-frozen samples from newly diagnosed patients 
with HL treated with ABVD or equivalent regimens [68]. 
Among the patients whose disease did not respond to 
treatment,  genes  signatures  of  tumor-related  macro-
phages and monocytes, angiogenic cells, adipocytes, and 
HRS  cells  were  overexpressed,  and  gene  signatures  of 
germinal  center  B  cells  were  underexpressed.  These 
findings were confirmed in an independent cohort of 166 
patients,  using  immunohistochemical  analysis.  An 
increased  number  of  CD68+  macrophages  correlated 
with  shorter  progression-free  survival  (PFS)  after 
primary  treatment  and  lower  relapse  rates  after 
autologous stem cell transplantation. In the multivariate 
analysis, CD68 outperformed the IPS score for predicting 
disease-specific  survival  (DSS).  Interestingly,  using  this 
score it was possible to identify a subset of patients with 
early-stage disease (stage I and II according to the Ann 
Arbor staging system) who had fewer than 5% CD68+ 
cells,  with  a  disease-specific  survival  rate  of  100% 
(Table  3).  These  results  were  consistent  with  findings 
reported  by  other  groups  [66,69]  that  analyzed  the 
prognostic value of tumor-infiltrating macrophages and 
lack of CD20+ B cells in the tumor microenvironment.
The results of Steidl et al. are of particular importance 
as pretreatment measurement of CD68 can be used to 
identify not only patients at high-risk of disease relapse 
or  progression  but  also  those  with  early-stage  disease; 
patients who have an excellent prognosis are currently 
overtreated  with  the  available  chemoradiotherapeutic 
approaches.  The  prognostic  value  of  CD68+  tumor-
infiltrating  macrophages  has  also  been  reported  in  a 
recent  study  of  288  patients  with  cHL  [70].  From  a 
biological point of view, tumor-associated macrophages 
have  been  associated  with  adverse  outcomes  in  many 
different  types  of  cancer,  and  they  are  now  known  to 
mediate  tumor  vessel  formation  through  secretion  of 
vascular endothelial growth factor and hypoxia-inducible 
factor 1α [23,71,72].
Infiltrating B cells
In  another  study,  Chetaille  et  al.  (2009)  analyzed  the 
gene-expression profiles of a set of 63 cHL samples from 
patients  with  early-  and  advanced-stage  disease  using 
DNA microarrays. The authors found that expression of 
the  B-cell  gene  signature  was  associated  with  better 
outcomes [49]. In addition, an increase in the number of 
CD20+  infiltrating  B  cells,  as  analyzed  by  immuno-
histochemical  analysis,  was  associated  with  improved 
outcomes (Table 3). These results highlight the relevance 
of  a  B-cell  reactive  infiltrate  for  an  efficient  immune 
response. Interestingly, Chetaille et al. showed that the 
molecular  profile  of  EBV-positive  tumors  was 
significantly different from that of EBV-negative tumors 
and  was  characterized  by  a  specific  T-helper  cell  1 
Table 3. Prognostic factors related to the tumor microenvironment
Factor Cell type Number of patients Significance, univariatea Significance, multivariatea Reference(s)
FOXP3 Treg 926 
257 
  98 
146
+ (↑FFS)
+ (↑DFS)
+ (↑FFS)
–
+ (↑FFS)
NA 
NA 
–
[64] 
[65] 
[50] 
[49]
FOXP3/TIA1 Treg/CD8+ T cells 257 + (↓EFS, DFS) + (↓EFS, DFS) [65]
GrB Activated; CD8+ T cells 257 
267 
  98 
146
– 
+ (↓OS)
– 
–
– 
+ (↓OS)
– 
–
[65] 
[66] 
[50] 
[49]
TIA1 CD8+ T cells 257 
267 
146 
  59
+ (↓EFS, DFS)
+ (↓EFS, DFS, OS)
+ (↓EFS)
+ (↓PFS)
NA 
+ (↓EFS, DFS, OS)
– 
+ (↓PFS)
[65] 
[66] 
[49] 
[48]
FOXP3/GrB Treg/activated; CD8+ T cells   98 + (↓FFS, OS) + (↓FFS) [50]
CD68 TAM 166 
288
+ (↓PFS, DFS, DSS)
+ (↓EFS, OS)
+ (↓DFS)
+ (↓OS)
[68] 
[70]
FOXP3/CD68 Treg/TAM 122 + (↓FFS, OS) NA [67]
CD20 Background B cells 166 
146
+ (↑PFS)
+ (↑EFS)
– 
+ (↑EFS)
[68] 
[49]
aThe presence (+) or absence (–) of a significant correlation (positive ↑ or negative ↓) with the study endpoints.
DSS, disease-specific survival; DFS, disease-free survival; EFS, event-free survival; FFS, failure-free survival; FOXP3, forkhead box P3; GrB, granzyme B; HLA, human 
leukocyte antigen; NA, not applicable; OS, overall survival; PFS, progression-free survival; TAM, tumor-associated macrophage; TIA1, cytotoxic granule-associated RNA-
binding protein; Treg, regulatory T cell.
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strategies [49].
In addition, the study by Steidl et al. [68] showed that 
CD20  expression  in  small  B  cells  (as  detected  by 
immunohistochemical  analysis)  was  associated  with 
prolonged PFS in the univariate analysis but was not an 
independent  predictor  of  prognosis  in  the  multivariate 
analysis. On the other hand, the number of CD20+ HRS 
cells, which was analyzed separately, was not associated 
with  treatment  outcomes.  Previously  published  studies 
evaluating  the  role  of  CD20+  HRS  cells  detected  by 
immunohistochemical analysis have reported conflicting 
results [48,73-75]. Therefore, we conclude that there is no 
consensus  on  the  prognostic  significance  of  CD20+ 
expression  in  HRS  cells  as  an  immunohistochemical 
marker (Table 3). However, the association of high levels 
of intratumoral B cells with good outcomes is consistent 
with the excellent prognosis of the LRHL subgroup.
Identifying novel genes associated with disease 
outcome in HL
Recently,  three  sequential  studies  using  gene  expression 
profiling of paraffin-embedded HL tissue samples from the 
Spanish Hodgkin Lymphoma Study Group described the 
impact of different gene expression signatures related to 
both HRS cells and the HL microenvironment on treat-
ment outcomes [76-78]. In the first two studies [76,78], the 
investigators  identified  a  group  of  genes  differentially 
expressed  in  HRS  cells  and  the  HL  tumor  micro-
environment that were demonstrated to signifi  cantly affect 
outcomes in HL. These genes belonged to several pathways 
already known to be involved in HL pathogenesis: the G2/
M  transition  and  spindle  check  point  (for  example, 
AURKA, MAD2L1, BUB1B, and CDK1), drug resistance 
and metabolism (the gene encoding topoisomerase 2a, and 
TYMS,  and  RRM2),  the  chaperone  pathway,  and  genes 
related  to  the  activity  of  the  tumor  microenvironment 
(T-cell and monocyte/macrophage activation).
In the most recent study, the prognostic impact of 30 
genes chosen on the basis of the previous two studies was 
evaluated  in  282  paraffin-embedded  cHL  samples  in 
order  to  build  a  prognostic  model  [77].  A  model  that 
included 11 genes belonging to four functional pathways 
(that  is,  apoptosis,  cell-cycle  regulation,  macrophage 
activation,  and  interferon  regulatory  factor  4)  could 
predict the risk of relapse and when integrated with the 
clinical variable stage IV, allowed the identification of a 
subgroup characterized by dismal outcomes (5-year FFS 
of 25%). Table 4 summarizes the most important genomic 
studies of outcome in cHL.
Predicting treatment outcome in HL
Recent  studies  have  identified  novel  genes  related  to 
chemotherapy response, including refractory disease. In 
addition,  the  prognostic  value  of  tools  for  functional 
imaging  (FDG-PET)  and  assessment  of  thymus  and 
activation-regulated  chemokine  (TARC)  levels  during 
treatment has been investigated.
Identifying novel genes associated with response to 
chemotherapy in HL
A  subset  of  patients  has  disease  that  is  refractory  to 
primary  standard  chemotherapy  (primary  refractory 
disease),  and  these  patients  have  dismal  outcomes 
following all subsequent treatments [23]. Even with high-
dose  chemotherapy  followed  by  autologous  stem  cell 
transplantation, only a minority of patients with primary 
refractory  disease  can  be  cured  [79].  This  group  of 
patients  can  be  well  defined  regarding  their  treatment 
outcomes;  however,  no  prognostic  score  or  diagnostic 
tools are available for the early identification of patients 
at very-high risk for failure of induction therapy.
Table 4. Genomic studies of outcome in classical Hodgkin lymphoma
Technique
Number 
of cases Material
HRS 
microdissection
HRS cell-related gene signatures 
associated with worse outcome
ME-related gene signatures 
associated with worse outcome Reference
GEP 29 Paraffin-embedded 
tissue
No Cell cycle  Macrophages, T cells [78]
RT-PCR array 52 Paraffin-embedded 
tissue
No G2/M transition, G1 phase, chaperone 
pathway, MAPK pathway, apoptosis
Monocytes, macrophages, T cells [76]
GEP 282 Paraffin-embedded 
tissue
No Cell cycle, apoptosis, IFR4 Macrophages [77]
GEP 63 Frozen fresh tissue  No BCR signalling, apoptosis, cell metabolism Stroma remodeling [49]
GEP 130 Frozen fresh tissue No HRS cell related genes Macrophages, angiogenic cells, 
monocytes
[68]
aCGH 53 Frozen fresh tissue Yes Gains of 16p (ABCC1) NA [81]
aCGH 27 Paraffin-embedded 
tissue
Yes 4q27 loss (IL2/IL21), 17p12 loss, 
19q13.3 gain (BCL3/RELB)
NA [82]
aCGH, array comparative genomic hybridization; BCR, B-cell receptor; GEP, gene-expression profile; HRS, Hodgkin and Reed-Sternberg (cell); MAPK, mitogen activated 
protein kinase; ME, microenvironment; SNP, single-nucleotide polymorphism.
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imbalances in microdissected HRS cells, analyzed using 
aCGH  [80].  Several  genes  belonging  to  the  main  cell-
survival pathways known to be activated in HL (that is, 
those  encoding  JAK/STAT,  NF-κB,  and  AP1-JUN-B) 
were found to be affected. However, the authors did not 
analyze the correlation between these gene imbalances 
and outcomes. Recently, Steidl and coworkers reported 
the results of a genome copy-number aCGH analysis in 
microdissected HRS cells from two groups of patients: 
those with disease that was responsive to primary therapy 
and  those  with  disease  that  was  refractory  to  primary 
therapy  (Table  4)  [81].  Copy  number  gains  on 
chromosome  16p  were  significantly  more  frequent  in 
patients  with  primary  refractory  disease  and  strongly 
correlated  with  prognosis  after  ABVD  chemotherapy. 
More  than  80%  of  patients  with  primary  refractory 
disease had gains on 16p, compared with 33% of patients 
with early-disease relapse, and 25% of patients with late-
disease  relapse.  Interestingly,  the  multidrug  resistance 
gene ABCC1, which is overexpressed in a variety of solid 
tumors, is located on cytoband 16p13.11 (Table 4).
In  addition,  frequent  losses  on  4q27  (harboring  the 
IL2/IL21 genes) and 17p12, and gains on 19q13.3 (BCL3/
RELB)  were  recently  described  to  be  associated  with 
resistance to ABVD chemotherapy in cHL [82]. Lourenço 
et  al.  (2010)  investigated  the  influence  of  genetic 
polymorphisms  in  the  gene  encoding  glutathione  S-
transferase (an enzyme family involved in the metabolism 
of alkylating agents and anthracyclines) on the outcomes 
of 125 patients with cHL [83]. Specific polymorphisms of 
genes  encoding  glutathione  S-transferase  significantly 
affected  DFS  and  OS  and  were  associated  with  higher 
chemotherapy  toxicities  (Table  4).  These  studies 
represent  excellent  examples  of  how  new  genomic 
technologies can be used to select prognostic factors and 
functionally evaluate their role in oncogenesis.
Prognostic value of modifications of functional imaging 
and TARC levels during treatment
FDG-PET scan
In  contrast  to  normal  differentiated  cells,  which  rely 
primarily on mitochondrial oxidative phosphorylation to 
generate the energy needed for cellular functions, most 
cancer  cells  rely  on  aerobic  glycolysis,  a  phenomenon 
termed ‘the Warburg effect’ [84,85]. For these reasons, 
neoplastic lymphocytes utilize higher amounts of glucose 
than their normal counterparts [86]. Fluorine-18 FDG-
PET  is  a  functional  imaging  test  that  measures  FDG 
uptake by cells, and is used in the management of both 
HL and non-HL.
In the case of HL, the HRS cells in the tumor tissue 
display  low  and  variable  expression  of  glucose 
transporters,  and  the  levels  of  these  transporters  and 
FDG uptake in tumor cells have not been reported to be 
correlated  [87,88].  In  contrast,  the  non-neoplastic 
inflammatory  cells  that  comprise  the  tumor 
microenvironment  show  high  FDG  uptake,  which  is 
further increased by exposure to inflammatory cytokines 
[88]. Because more than 90% of the entire tumor mass is 
composed  of  these  inflammatory  cells  in  HL,  we  can 
conclude that the FDG uptake may be viewed primarily 
as a biomarker for the metabolic activity of the tumor 
microenvironment.
Studies that have assessed FDG-PET as a prognostic 
tool used during chemotherapy have reported that it is 
useful for predicting poor outcomes and building a risk-
adapted therapy approach in HL. A study conducted by 
Gallamini et al. (2007) showed a 2-year PFS of 12% for 
cHL patients with a positive interim PET scan after two 
cycles of ABVD chemotherapy, compared with 95% for 
patients  with  negative  interim  PET  scans  [25]. 
Remarkably,  in  that  study  interim  PET  was  more 
predictive of outcome than the IPS score. Other reports 
have shown similar results [26,27] (Table 5).
However,  because  all  studies  published  to  date  have 
been retrospective, the prognostic value of interim PET 
needs to be validated in a prospective study. Furthermore, 
the  interpretation  of  interim  PET  scans  should  be 
standardized. On the basis of the results of these studies, 
many  recent  prospective  clinical  trials  have  been 
designed  to  build  risk-directed  therapy  algorithms  in 
order to minimize chemotherapy cycles, with the goal of 
eventually avoiding radiotherapy for patients with early 
negative-interim PET scans and intensifying treatment in 
patients with positive-interim PET scans [28].
Table 5. Early predictors of response to chemotherapy in HL: interim PET and serum TARC levels
Factor Number of patients Significance, univariate Significance, multivariate Reference(s)
Interim PET   77 
260 
  40
+ (PFS) 
+ (PFS) 
+ (PFS)
+ (PFS) 
+ (PFS) 
NA
[26] 
[25] 
[27]
TARC
Basal and after therapy)   62 + (OS, RR) NA [92]
After one cycle, mid and after treatment   63 + (RR) NA [93]
The presence (+) or absence (–) of a significant correlation with the study endpoints is given. NA, not applicable; OS, overall survival; PET, positron emission 
tomography; PFS, progression-fee survival; RR, response rate; TARC, thymus and activation-regulated chemokine.
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interim PET and the fact that FDG uptake reflects the 
metabolic activity of the surrounding inflammatory cells 
rather than the HRS cells again highlights the importance 
of the tumor microenvironment in the pathogenesis of 
HL.  Because  accurate  PET  results  depend  on  intact 
glucose  transporter  mechanisms  in  cell  membranes, 
caution should be exercised when PET is used to evaluate 
response to investigational targeted agents that may alter 
the expression of glucose transporter proteins [89].
Thymus and activation-regulated chemokine
TARC  is  a  chemokine  normally  produced  by  antigen-
presenting cells, such as dendritic cells. TARC attracts T-
helper  2  cells  through  its  interaction  with  the  C-C 
chemokine  receptor  type  4  [90].  HRS  cells  secrete  an 
abundant amount of TARC, contributing to the attraction 
and  homing  of  activated  Th2  lymphocytes  [3,56,91]. 
Elevated pretreatment levels of TARC production have 
been correlated with adverse outcomes in patients with 
HL  [92],  and  permanently  high  TARC  levels  after 
treatment are related to shorter PFS and OS (Table 3). In 
a  recent  preliminary  study,  changes  in  plasma  TARC 
levels before and during treatment were correlated with 
the  results  of  functional  metabolic  PET  imaging  [93]. 
Interestingly,  mid-treatment  plasma  TARC  levels 
outperformed  mid-treatment  FDG-PET  imaging  in 
predicting  response  to  therapy,  and  after  one 
chemotherapy cycle TARC levels could be used to predict 
final  response  to  treatment  (Table  5).  A  prospective 
evaluation of TARC levels before and during treatment in 
future clinical trials is needed to confirm the prognostic 
value of plasma TARC levels in predicting outcomes in 
cHL patients. If these preliminary results are confirmed, 
we suggest that it might be more practical to measure 
interim TARC than to use interim PET, as this approach 
is cheaper and the results are more reproducible across 
different centers.
Future outlook and conclusions
Several  new  prognostic  factors  for  HL  have  been 
identified during the past 10 years. However, the majority 
of  the  reports  of  prognostic  factors  for  HL  are 
retrospective  analyses,  and  the  results  need  to  be 
validated  prospectively  before  using  them  in  clinical 
practice. The ultimate goal of using prognostic markers 
to  predict  outcomes  is  to  achieve  a  personalized 
therapeutic  approach,  avoiding  overtreatment  and 
toxicity  for  some  patients,  and  undertreatment  or 
exposure to ineffective cytotoxic agents for other patients 
at  higher  risk  of  disease  relapse.  New  genomic 
technologies have allowed a better understanding of the 
pathogenesis  of  cHL,  with  the  identification  of 
polymorphisms associated with increased risk of disease 
and alteration of genes involved in response to treatment. 
Furthermore,  gene  expression  profiling  studies  have 
identified  specific  gene  signatures  associated  with 
outcomes (for example, tumor-infiltrating macrophages 
and  B  cells)  that  could  be  easily  detected  by  specific 
immunohistochemical  markers  expressed  on  the  cell 
surface (for example, Bcl-2, CD68, CD20, and FOXP3).
It is now becoming clear that cHL, considered in the 
past to be a single disease entity with some pathological 
variants, comprises many different diseases characterized 
by  distinct  biologies,  prognostic  biomarker  expression 
profiles,  and  response  to  therapies.  In  addition,  recent 
progress  in  the  functional  imaging  and  monitoring  of 
biomarkers during treatment have provided the basis for 
a risk-adapted therapy approach that is currently being 
tested in clinical trials.
The  identification  of  new  biomarkers  in  HL  may 
provide  potential  targets  for  the  development  of  new 
treatment  agents.  HRS  cells  display  simultaneous 
activation  of  different  cell-survival  pathways,  including 
NF-κB,  JAK/STAT,  PIP3K/AKT/mTOR,  NOTCH,  and 
RAF/MEK/ERK,  and  many  different  drugs  against 
various  targets  are  now  being  evaluated  clinically 
(Table 6; Figure 1) [94-103]. The final results from a phase I 
Table 6. New agents for Hodgkin lymphoma currently under clinical development
Target Agent  Phase Response (PR+CR) (%) Reference(s)
CD30 Brentuximab, Vedotin I 50 [94]
CD20 Rituximab II 22 [95]
mTOR Everolimus II 47 [96]
JAK2 SB1518  I – [97]
HDACs LBH 589 
SAHA 
MGCD0103
II 
II 
II
26 
  4 
30
[98] 
[99] 
[100]
AKT MK2206 I – –
NF-kB Bortezomib II 7 [101]
Target unknown Lenalidomide II 13 to 17 [102,103]
CR, complete response; HDACs, histone deacetylases; JAK2, Janus kinase 2; mTOR, mammalian target of rapamycin; NF, nuclear factor; PR, partial response.
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conjugated  with  the  anti-tubulin  agent  monomethyl 
auristatin E) in patients with relapsed CD30+ lymphomas 
have recently been reported [94]: in a group of 45 heavily 
pretreated patients, 86% experienced reductions in their 
tumor size, with 24% complete responses. These results 
confirm that the rational identification of new targets and 
new agents may have a significant impact on the natural 
history of this disease. Even though many of these new 
drugs  have  shown  little  activity  as  single  agents,  the 
simultaneous targeting of multiple survival pathways and 
the  tumor  microenvironment  through  rationally 
designed treatment combinations could further enhance 
their activity.
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Figure 1. Prognostic factors, pathways, and potential therapeutic targets involved in the pathogenesis of classical Hodgkin lymphoma. 
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